EUVIMEDEUVIMED entdecken
Klinische Studie (Phase IV)Open Access · CC BY-NC-ND 4.0

Safety and Efficacy Assessment of Trastuzumab Emtansine in Indian Patients With Human Epidermal Growth Factor Receptor 2‐Positive Unresectable Locally Advanced or Metastatic Breast Cancer Previously Treated With Trastuzumab and a Taxane: An Open‐Label, Single‐Arm, Phase IV Study

Sudeep Gupta iD, Manish Singhal, Shona Nag, Waseem Abbas, Dinesh Chandra Doval, Hari Goyal, Chirag Shah, Ashish Singh, Radheshyam Naik, Nitesh Rohatgi, Poonam Patil, Shyam Aggarwal und 2 weitere

Asia-Pacific Journal of Clinical Oncology · 2025

DOI: 10.1111/ajco.70007 ↗

Kurz gefasst

Klinische Studie (Phase IV) in der Zeitschrift Asia-Pacific Journal of Clinical Oncology, 2025. Verfasst von Sudeep Gupta und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Antineoplastic Combined Chemotherapy Protocols, Antineoplastic Agents, Immunological. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Roche Products (India) Pvt. Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Trastuzumab emtansine (T‐DM1), an antibody–drug conjugate, targets tumor cells overexpressing human epidermal growth factor receptor 2 (HER2). This single‐arm, phase IV study assessed the safety and efficacy of T‐DM1 in Indian patients with HER2‐positive, locally advanced, or metastatic breast cancer previously treated with trastuzumab and a taxane.

Methods

Patients received T‐DM1 (3.6 mg/kg intravenously every 3 weeks) until death, disease progression, unacceptable toxicity, consent withdrawal, or up to a maximum of 12 months after the last patient's first visit, whichever occurred first. Safety was mainly assessed by the incidence and severity of adverse events (AEs). Efficacy was evaluated by progression‐free survival (PFS), overall survival (OS), and overall response rate (ORR). Patients were followed up posttreatment until 12 months or until lost to follow‐up, withdrawn consent, or death.

Results

A total of 70 eligible patients (median age [range]: 50.0 [27.0–75.0] years) received at least one dose of T‐DM1 (median duration [range]: 32.0 [1.0–125.0] weeks). Adverse events in 21 (30.0%) patients were treatment‐related. The most common treatment‐related AEs and SAEs were thrombocytopenia (seven [10.0%] and three [4.0%] patients, respectively) and epistaxis (four [6.0%] and two [3.0%] patients, respectively). During the study, 10 (18.0%) patients died (disease progression: n = 6; AE: n = 3; and unknown reason: n = 1), while 2 patients died during the follow‐up period. Median PFS was 14 months (95% confidence interval [CI]: 8.0, 17.0). Among 65 evaluable patients, 16 (23.0%) achieved partial responses; ORR was 23.0%.

Conclusions

Trastuzumab emtansine was found to be safe and efficacious in the Indian patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesAntineoplastic Combined Chemotherapy ProtocolsAntineoplastic Agents, ImmunologicalMaytansineHumansFemaleMiddle AgedAdo-Trastuzumab EmtansineTrastuzumabAdultAgedTaxoidsIndiaBridged-Ring CompoundsNeoplasm Metastasis

Stichwörter der Autor:innen

HER2‐positive breast cancerHER2‐positive trastuzumab‐emtansineantibody–drug conjugatemetastatic breast canceropen‐labelsafety and efficacytrastuzumab emtansine

Substanzen

Ado-Trastuzumab EmtansineTrastuzumabErb-b2 Receptor Tyrosine KinasesERBB2 protein, humanTaxoidstaxaneBridged-Ring CompoundsAntineoplastic Agents, ImmunologicalMaytansine

Autor:innen und Institutionen

  • Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India.
  • Indraprastha Apollo Hospitals, New Delhi, India.
  • Jehangir Hospital, Pune, Maharashtra, India.
  • Medical Oncology, Max Super Speciality Hospital, New Delhi, India.
  • Medical Oncology, Rajiv Gandhi Cancer Institute and Research Center, New Delhi, India.
  • Artemis Health Institute, Gurugram, Haryana, India.

ORCID-Profile: Sudeep Gupta

Förderung

  • Roche Products (India) Pvt. Ltd.

Zitieren

APA

Gupta, S., Singhal, M., Nag, S., Abbas, W., Doval, D. C., Goyal, H., Shah, C., Singh, A., Naik, R., Rohatgi, N., Patil, P., Aggarwal, S., Raina, V., & Watts, V. (2025). Safety and Efficacy Assessment of Trastuzumab Emtansine in Indian Patients With Human Epidermal Growth Factor Receptor 2‐Positive Unresectable Locally Advanced or Metastatic Breast Cancer Previously Treated With Trastuzumab and a Taxane: An Open‐Label, Single‐Arm, Phase IV Study. Asia-Pacific Journal of Clinical Oncology. https://doi.org/10.1111/ajco.70007

Vancouver

Gupta S, Singhal M, Nag S, Abbas W, Doval DC, Goyal H, et al. Safety and Efficacy Assessment of Trastuzumab Emtansine in Indian Patients With Human Epidermal Growth Factor Receptor 2‐Positive Unresectable Locally Advanced or Metastatic Breast Cancer Previously Treated With Trastuzumab and a Taxane: An Open‐Label, Single‐Arm, Phase IV Study. Asia-Pacific Journal of Clinical Oncology. 2025. doi:10.1111/ajco.70007

BibTeX
@article{Gupta2025,
  author = {Gupta, Sudeep and Singhal, Manish and Nag, Shona and Abbas, Waseem and Doval, Dinesh Chandra and Goyal, Hari and Shah, Chirag and Singh, Ashish and Naik, Radheshyam and Rohatgi, Nitesh and Patil, Poonam and Aggarwal, Shyam and Raina, Vinod and Watts, Vaibhav},
  title = {Safety and Efficacy Assessment of Trastuzumab Emtansine in Indian Patients With Human Epidermal Growth Factor Receptor 2‐Positive Unresectable Locally Advanced or Metastatic Breast Cancer Previously Treated With Trastuzumab and a Taxane: An Open‐Label, Single‐Arm, Phase IV Study},
  journal = {Asia-Pacific Journal of Clinical Oncology},
  year = {2025},
  doi = {10.1111/ajco.70007}
}
Kostenlos starten →